← boardnext 2027-02
SXTP
60 Degrees Pharmaceuticals LLCdistress 5/10 · elevated risk$1.52-2%today-85% from 52w high
Lead: severe babesiosis
Revenue
pre-revenue
Liquidity
$5M
Runway
0.6 yrs
Shares 1y
-35%
Price & events
-69.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-0.2%
1W
-9.7%
1M
-11.3%
3M
-66.6%
6M
-71.7%
1Y
-96.6%
2Y
—
5Y
-99.9%
All
Overview
- Market Cap
- $4.03M
- Enterprise Value
- $844.81K
- Volume
- 10.54K
- 52 Week Range
- $1.36 – $10.08
- Total Shares
- 2.66M
- Float Shares
- 2.43M
- Short %
- 4.26%
- % Held by Insiders
- 0.88%
- % Held by Institutions
- 9.60%
- RVOL
- 0.09x
- Beta
- 2.48
Pipeline stages · 1 programs
Tafenoquine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-02 Estimated 50% readout ~2027-03-18 | Phase 2 | Tafenoquine 100mg | Chronic Babesiosis | — | recruiting |
| 2027-03-01 Estimated 50% readout ~2027-04-15 | Phase 2 | Tafenoquine | Babesiosis | — | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 5
- before the end of the first quarter of 2028Guided 70%regulatory submissionFiled (NDA/BLA)tafenoquine · Plan to submit NDA to FDA for tafenoquine in severe babesiosisSEC 8-K
- earlier of 10/30/2026 or after 24 patients randomized and followed for at least 50 daysreadouttafenoquine · interim analysis for conditional power and potential early stopping or sample size reassessmentSEC 8-K
- September 9, 2025conferencedata presentationsecondaryCEO Geoff Dow presents investor information at H.C. Wainwright conference.SEC 8-K
- 2025-04-04partnershipcastanospermine · Entered option agreement to negotiate exclusive license for large-scale purification of castanospermine from Florida State University Research Foundation.SEC 8-K
- 2024-07-25partnershipARAKODA · Awarded $311,862 contract with US Army for packaging validationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 2,659,288 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-22Ascendiant CapitalBuy
- 2026-05-20HC Wainwright & Co.Buy → Neutral
- 2026-04-09Ascendiant CapitalBuy
- 2026-01-27HC Wainwright & Co.Buy
- 2025-11-28Ascendiant CapitalBuy
- 2025-09-03Ascendiant CapitalBuy
Competitors — severe babesiosis
- none identified
Recent news
- 2026-07-2360 Degrees Pharmaceuticals (SCTP) Registration Filing Summary - Quartr
- 2026-07-2160 Degrees Pharmaceuticals: FDA-Approved Malaria & Babesiosis Treatments, Clinical Pipeline, and Commercial Growth (2026 Investor Update) – Minichart - Minichart
- 2026-07-2060 Degrees updates strategy for ARAKODA and profitability - TipRanks
- 2026-07-11Enterprise value to EBITDA forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
- 2026-07-09Price to earnings forward of 60 Degrees Pharmaceuticals, Inc. – NASDAQ:SXTP - TradingView
- 2026-07-0960 Degrees Pharmaceuticals (SXTP) sets tafenoquine babesiosis interim analysis and sNDA path - Stock Titan
- 2026-07-0860 Degrees Pharmaceuticals Announces Exclusive Option - GlobeNewswire
- 2026-07-0860 Degrees Pharma gets option to pursue tick-borne disease drug - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.